



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.
E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

To,

Date: 27.06.2020

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting

Ref: Our Company's letter dated 17.06.2020

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Saturday, 27.06.2020 at 5:00 p.m. at the registered office of the company the following were considered and approved:

1. Audited financial results for the quarter and year ended 31.03.2020. (Enclosed)
2. Auditors Report along with Declaration as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for year ended 31.03.2020. (Enclosed)

The meeting concluded at 6⁰⁰ p.m.

This is for the information and records of the Exchange, please.

Thanking you.


Yours faithfully,
For Concord Drugs Limited

S. Koni Reddy



S. KoniReddy
Whole-time Director & CFO
DIN: 02829319


Encl: as above





CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2020					
[Rs. in Lakhs]					
Particulars	Quarterly ended			Year ended	
	31-Mar-20 (Audited)	31-Dec-19 (Unaudited)	31-Mar-19 (Audited)	31-Mar-20 (Audited)	31-Mar-19 (Audited)
I Revenue from Operations					
a. Net sales from Operations	1,302.822	1,090.557	1,434.451	5,133.885	4,807.725
b. Other Operating Income	4.551	2.152	2.161	12.010	8.587
II Other Income					
III Total Revenue (I+II)	1,307.374	1,092.709	1,436.612	5,145.895	4,816.312
IV Expenses					
a. Cost of Material Consumed	1,116.820	876.245	1,342.936	4,206.017	3,913.852
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	20.650	1.288	50.732	51.718	45.587
c. Employees Benefit Expenses	84.782	89.589	34.149	350.716	252.921
d. Finance Costs	26.959	40.098	38.976	154.373	159.299
e. Depreciation and Amortisation expense	36.279	36.887	7.349	146.390	171.177
f. Other expenses	48.188	44.817	37.548	191.034	229.500
Total Expenses	1,292.379	1,086.349	1,410.228	5,100.247	4,772.335
V Profit/ (Loss) before Exceptional item and tax (III-IV)	14.994	6.361	26.384	45.648	43.977
VI Exceptional Items					
VII Profit/ (Loss) before tax (V-VI)	14.994	6.361	26.384	45.648	43.977
VIII Tax Expense:					
a. Current tax	3.279	1.932	5.861	12.822	3.275
b. Deferred tax charge/credit	3.027	1.655	3.499	11.909	11.718
	0.252	0.277	9.361	0.913	8.443
IX Profit/ (Loss) for the period (VII-VIII)	11.715	4.429	20.523	32.826	40.703
X Other Comprehensive Income					
Items that will not be reclassified to profit or loss					
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	11.715	4.429	20.523	32.826	40.703
XI Paid-up equity share capital (Face value of the share- Rs. 10 each)	874.375	874.375	786.175	874.375	786.175
Other Equity	1,474.082	1,464.770	1,529.456	1,474.082	1,529.456
XII Earnings per share (of Rs. 10 each)					
XIII a. Basic (in Rs)	0.134	0.05	0.26	0.375	0.52
b. Diluted (in Rs)	0.134	0.05	0.26	0.375	0.52
Notes:					
1	The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.				
2	The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 27th June, 2020				
3	The company adopted the Indian Accounting standards (Ind AS) from 01.04.2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. Note: The figures for the qtr ended March 31, 2020 are balancing figures between the Audited figures of the full financial year ended 31, March 2020 & the published year to date figures upto 9 months ended Dec 31, 2019				
4	Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.				
5	The results are also available on the website of the Company www.concorddrugs.in.				
By Order of the Board For Concord Drugs Limited  Managing Director DIN: 01764665					
Place: Hyderabad Date: June 27, 2020					





CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com

Website : www.concorddrugs.in

Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana			
Balance sheet as at 31st March 2020			
Particulars	Note	As At March 31, 2020	As at March 31, 2019
ASSETS			
Non-current assets			
(a) Property, plant and equipment	3	973.864	1,106.32
(b) Capital Work-in Progress	3	99.773	28.89
(b) Investment property	3	78.598	78.60
Financial assets			
(a) Loans & Advances	5	53.616	50.02
(b) Trade receivables	6		
Other Non current assets	4	39.291	39.26
Total Non - Current Assets		1,245.142	1,303.08
Current Assets			
Inventories	7	1,643.126	1,864.15
Financial assets			
(a) Investments			
(b) Trade receivables	6	2,544.596	4,843.47
(c) Cash and cash equivalents	8	1.210	15.89
(d) Bank balances other than (c) above	8	2.592	2.59
(e) Other Current Financial Assets	9	4.130	4.13
Other current assets	10	360.750	243.53
Total Current assets		4,556.405	6,973.77
Total Assets		5,801.546	8,276.85
EQUITY AND LIABILITIES			
Equity			
Equity share capital	11	874.375	786.18
Other equity	12	1,474.470	1,529.46
Total Equity		2,348.845	2,315.63
Non-current liabilities			
Financial Liabilities			
(a) Borrowings	13	87.723	68.97
(b) Trade payables			
Deferred tax liabilities, net	14	13.705	12.79
Provisions	15	208.383	217.23
Government Grants	13	45.526	54.13
Total Non-current liabilities		355.337	353.13
Current liabilities			
Financial liabilities			
(a) Borrowings	16	869.101	913.68
(b) Trade payables	17	1,279.617	4,263.73
(c) Other Current financial liabilities	18		
Current tax liabilities, net	15	11.521	11.72
Other current liabilities	19	937.126	418.96
Total Current liabilities		3,097.365	5,608.09
Total liabilities		3,452.702	5,961.22
Total Equity and liabilities		5,801.546	8,276.85

Corporate information and significant accounting policies

1 & 2



For N.G Rao and Associates
Chartered Accountants
FRN- 0093995

SD/-
G. Nageswara Rao
Partner
Mno-207300
Place: Hyderabad
Date: 27/06/2020

For and on behalf of the Board of Directors of
Concord Drugs Limited

S. Nagi Reddy
Managing Director
DIN:01764665

S. Koni Reddy
Koni Reddy Seelam
Executive Director
DIN: 02829319





CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsLtd@gmail.com Website : www.concorddrugs.in

To,

Date: 27.06.2020

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Dear Sir,

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

I, S. Koni Reddy, Whole-time Director & CFO of Concord Drugs Limited hereby declare that, the statutory Auditors of the company, M/s. NG Rao & Associates Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company for the quarter and year ended 31st March, 2020.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you.

Yours faithfully,
For Concord Drugs Limited

S. Koni Reddy




S. Koni Reddy
Whole-time Director & CFO
DIN: 02829319



INDEPENDENT AUDITOR'S REPORT ON AUDIT OF STANDALONE FINANCIAL RESULTS
TO THE BOARD OF DIRECTORS OF CONCORD DRUGS LIMITED,

1. We have audited the accompanying statement of Standalone financial results of Concord Drugs Limited ('the company'), for the three months and year ended March 31, 2020 ('the Statement'), being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (the "Listing Regulations").
2. This statement is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act') as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the listing Regulations. Our responsibility is to express an opinion on the Statement based on our audit of such interim consolidated financial statement.
3. We conducted our audit of the Statement in accordance with the Standards on Auditing (SAs) issued by the Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the statement is free from material misstatement.


An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the statement. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the company's preparation and fair presentation of the statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal financial controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.



We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us, the statement
- a. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and
 - b. gives a true and fair view in conformity with Indian Accounting Standard 34 “Interim Financial Reporting” (Ind AS 34”) prescribed under Section 133 of the Companies Act 2013 (the “Act”) read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the three months and year ended March 31, 2020.

For N.G Rao and Associates
Chartered Accountants
FRN:009399S


G Nageswara Rao
(Partner)
MNo:207300
UDIN: 20207300AAAAIM3254

Place: Hyderabad
Date: 27-06-2020.

